Literature DB >> 29788868

Contribution of Spinal Cord Oligodendrocytes to Neuroinflammatory Diseases and Pain.

Sergio M Borghi1, Victor Fattori1, Miriam S N Hohmann1, Waldiceu A Verri1.   

Abstract

BACKGROUND: Neuroinflammatory diseases that affect spinal cord or associated spinal nerves represent challenging conditions for management in current medicine because of their complex pathology, poor prognosis, and high morbidity, which strikingly reduces the quality of life of patients. In this sense, a better understanding of the cellular and molecular mechanisms of spinal cord neuroinflammation might contribute to the development of novel therapies. Oligodendrocytes have unique and vital biological properties in central nervous system (CNS) homeostasis and physiology. A growing body of experimental evidence demonstrates that these glial cells are involved in the pathophysiological mechanisms underlying many chronic, neurodegenerative, and incapacitating CNS disorders. These cells also have important implications for the development and maintenance of neural plasticity and chronic pain states. On the other hand, evidence indicates that oligodendrocytes and their products may act in favor of CNS promoting beneficial effects orchestrating CNS tissue repair after injury.
OBJECTIVE: The present review aims to explore the multi-faceted actions of spinal cord oligodendrocyte progenitors cells (OPCs) and mature oligodendrocytes in CNS inflammation and pathology, addressing their roles in experimental and clinical settings. A major focus was given to spinal cord amyotrophic lateral sclerosis, multiple sclerosis (MS)/experimental autoimmune encephalomyelitis (EAE), traumatic injury and pain processing.
METHODS: This review analyses and discusses published original research articles regarding the role of OPCs/oligodendrocytes in spinal cord inflammation and pain processing. RESULTS AND
CONCLUSION: Findings from a number of clinical and experimental paradigms suggest spinal cord OPCs/oligodendrocytes are a potential therapeutic target for the control of neuroinflammation. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  OPCs; central sensitization; myelin; neuroinflammation; oligodendrocytes; spinal cord.

Mesh:

Year:  2019        PMID: 29788868     DOI: 10.2174/0929867325666180522112441

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  5 in total

Review 1.  Spinal Microglia and Astrocytes: Two Key Players in Chronic Visceral Pain Pathogenesis.

Authors:  Jun-Yi Long; Xue-Jun Wang; Xiao-Ying Li; Xie-He Kong; Guang Yang; Dan Zhang; Yan-Ting Yang; Zheng Shi; Xiao-Peng Ma
Journal:  Neurochem Res       Date:  2021-11-19       Impact factor: 3.996

Review 2.  Neuroinflammation Involved in Diabetes-Related Pain and Itch.

Authors:  Xiao-Xia Fang; Heng Wang; Hao-Lin Song; Juan Wang; Zhi-Jun Zhang
Journal:  Front Pharmacol       Date:  2022-06-20       Impact factor: 5.988

3.  Chemical approach to generating long-term self-renewing pMN progenitors from human embryonic stem cells.

Authors:  Guan-Yu Zhang; Zhu-Man Lv; Hao-Xin Ma; Yu Chen; Yuan Yuan; Ping-Xin Sun; Yu-Qi Feng; Ya-Wen Li; Wen-Jie Lu; Yu-Dong Yang; Cheng Yang; Xin-Lu Yu; Chao Wang; Shu-Long Liang; Ming-Liang Zhang; Hui-Liang Li; Wen-Lin Li
Journal:  J Mol Cell Biol       Date:  2022-02-24       Impact factor: 6.216

4.  Modulation of neuroglial interactions using differential target multiplexed spinal cord stimulation in an animal model of neuropathic pain.

Authors:  Ricardo Vallejo; Courtney A Kelley; Ashim Gupta; William J Smith; Alejandro Vallejo; David L Cedeño
Journal:  Mol Pain       Date:  2020 Jan-Dec       Impact factor: 3.395

5.  Spinal cord stimulation using differential target multiplexed programming modulates neural cell-specific transcriptomes in an animal model of neuropathic pain.

Authors:  David L Cedeño; William J Smith; Courtney A Kelley; Ricardo Vallejo
Journal:  Mol Pain       Date:  2020 Jan-Dec       Impact factor: 3.395

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.